Jin Medical International Ltd

Jin Medical International Ltd (ZJYL) Stock Analysis

$1.993

+0.055 (+2.75%)At close

Loading chart…
High
2.055
Open
1.954
VWAP
1.98
Volume
31.54K
Mkt Cap
402.33M
Low
1.900
Amount
62.53K
EV/EBITDA, TTM
0.00

Jin Medical International Ltd is a holding company mainly engaged in the design and manufacturing of wheelchairs. The Company, through its wholly owned subsidiaries, is primarily engaged in the design, development, manufacturing and sales of wheelchair and other living aids products to be used by people with disabilities or impaired mobility. The Company's wheelchair product category includes mid, high and low-end wheelchairs. The wheelchair components include wheels and brakes, which are sold to customers for after-sales service. The living aids product category consists of oxygen concentrators, bath aids and rehabilitative devices. The Company mainly distributes its products in domestic and overseas markets.

AI analysis of Jin Medical International Ltd (ZJYL)

Hold

Currently, Jin Medical International Ltd (ZJYL) is not a strong buy. The stock is trading at $2.05, which is significantly down 54.47% year-to-date and 67.17% over the past year. Although the RSI is at 48.154, indicating it is not overbought or oversold, the forward P/E ratio is exceptionally high at 147.30, suggesting that the stock may be overvalued. Additionally, the recent 1-for-20 reverse stock split has led to a 16% drop in premarket trading, raising concerns about investor confidence. The main risk is the stock's high valuation metrics, particularly the price-to-sales ratio of 7.76, which could deter long-term investors. Overall, while there are some positive projections based on historical patterns, the current financial indicators suggest caution.

Valuation Metrics

The current forward P/E ratio for Jin Medical International Ltd (ZJYL) is 0.00, compared to its 5-year average forward P/E of 0.00.

Forward P/E

Strongly Undervalued
5Y Average P/E
0.00
Current P/E
0.00
Overvalued
0.00
Undervalued
0.00

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued
0.00
Undervalued
0.00

Forward P/S

Strongly Undervalued
5Y Average P/S
0.00
Current P/S
0.00
Overvalued
0.00
Undervalued
0.00

Alphio AI Price Scenarios for ZJYL

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%ZJYL

$0.63

Scenario price

B

Base

Base · 50%ZJYL

$0.59

Scenario price

B

Bear

Bear · 25%ZJYL

$0.47

Scenario price

Events Timeline

2026-03-13 (ET)

20:00:00

Jin Medical International Ltd Trading Halted, News Pending

2025-07-16 (ET)

05:41:21

Jin Medical launches production at Plant No. 3

2025-05-06 (ET)

17:47:51

Jin Medical receives noncompliance notification from Nasdaq

2024-10-10 (ET)

08:11:23

Jin Medical announces initiation of construction of new manufacturing facility

News

ZJYL FAQ — answered by Alphio AI

Jin Medical International Ltd is a holding company mainly engaged in the design and manufacturing of wheelchairs. The Company, through its wholly owned subsidiaries, is primarily engaged in the design, development, manufacturing and sales of wheelchair and other living aids products to be used by people with disabilities or impaired mobility. The Company's wheelchair product category includes mid, high and low-end wheelchairs. The wheelchair components include wheels and brakes, which are sold to customers for after-sales service. The living aids product category consists of oxygen concentrators, bath aids and rehabilitative devices. The Company mainly distributes its products in domestic and overseas markets. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC, AND SURGICAL APPLIANCES AN industry).

Currently, Jin Medical International Ltd (ZJYL) is not a strong buy. The stock is trading at $2.05, which is significantly down 54.47% year-to-date and 67.17% over the past year. Although the RSI is at 48.154, indicating it is not overbought or oversold, the forward P/E ratio is exceptionally high at 147.30, suggesting that the stock may be overvalued. Additionally, the recent 1-for-20 reverse stock split has led to a 16% drop in premarket trading, raising concerns about investor confidence. The main risk is the stock's high valuation metrics, particularly the price-to-sales ratio of 7.76, which could deter long-term investors. Overall, while there are some positive projections based on historical patterns, the current financial indicators suggest caution.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading